Filing Details

Accession Number:
0000899243-19-013104
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-10 18:00:18
Reporting Period:
2019-05-08
Accepted Time:
2019-05-10 18:00:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1739458 Herm Cukier C/O Biodelivery Sciences Intl, Inc.
4131 Parklake Ave. Suite 225
Raleigh NC 27612
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-08 66,666 $0.00 66,666 No 4 M Direct
Common Stock Disposition 2019-05-08 29,425 $5.07 37,421 No 4 S Direct
Common Stock Disposition 2019-05-09 860 $4.92 36,381 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2019-05-08 66,666 $0.00 66,666 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
133,334 2021-05-08 No 4 M Direct
Footnotes
  1. The shares of common stock were acquired by the Reporting Person as a result of the vesting of 66,666 Performance Restricted Stock Units ("PRSUs") granted to the Reporting Person on May 2, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended , subject to certain performance measures. The remainder of the PRSUs under this grant will vest: i) one-half after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures and ii) the remaining half after the first open window upon the filing of the Company's Annual Report in March 2021 subject to certain performance measures. The PRSUs convert into common stock on a one-for-one basis.
  2. The shares of Common Stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of PRSUs.
  3. On May 8, 2019, the Reporting Person sold an aggregate of 29,425 shares of the Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.19 per share and the lowest sale price was $4.99 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in these footnotes.